Advances in the Treatment of Serious Systemic Fungal Infections--An Update - Market Research Reports

Printer Friendly

Printed from http://www.researchandmarkets.com/reports/314589

Advances in the Treatment of Serious Systemic Fungal Infections--An Update

Description:

Opportunistic fungal infections are a major problem in immunocompromised patients. In recent years, the number of patients with severe immunosuppression has risen dramatically as a result of advances in the treatment of HIV/AIDS, cancer, and other conditions. Many strains of fungi are developing resistance to current drugs, especially fluconazole. As this public health problem reaches a crisis, the available drugs (polyenes, azoles, pyrimidines, and the emerging echinocandins) have become inadequate to meet the task. Only a few antifungals have received approval in the United States, and these agents have notable limitations, including narrow spectrum of activity, toxicity (side effects), and emerging fungal resistance. The significant market opportunity for antifungal drugs has attracted many pharmaceutical and biopharmaceutical companies to become involved in R&D.

This report gives an overview of opportunistic and endemic fungal pathogens, current therapies, and emerging strategies that aim to treat this growing patient population.

Business Implications
- Many different types of fungi can cause serious systemic infections in humans, and opportunistic fungal infections are now recognized as a major problem in immunocompromised patients. In recent years, the number of patients with severe immunosuppression has increased dramatically as a result of advances in the life-prolonging treatment of patients with HIV/AIDS, cancer, and other conditions.

- The first antifungal drug to be approved in the United States, amphotericin B, received FDA approval in 1958. Despite its toxicity problems, amphotericin B is still widely used to treat fungal infections, and new formulations are in development. Overall, the antifungal therapeutic market has been stagnating since the introduction of caspofungin (Mercks Cancidas) and voriconazole (Pfizers Vfend), both of which were approved in the United States in 2001.

- New azoles and echinocandins are in late-stage development, and many companies have novel antifungals in early stages of development that are based on a wide variety of approaches. Additional research is ongoing to identify novel targets for the treatment of fungal infections.

- Other factors are changing the antifungals market. The expiration of the patent for Pfizer’s Diflucan (fluconazole) and the emergence of generic versions will have an immediate impact on the competitive landscape. Other influential trends include the growing use of prophylactic and empirical antifungal therapy, and a widening interest in the potential for combination therapy. We anticipate significant changes in the antifungal therapy market over the next few years.

Contents:

Introduction
Overview of Common Opportunistic and Endemic Fungal Pathogens
Current Therapies for Systemic Fungal Infections
Select Emerging Antifungal Therapies and Strategies
Prospects for Antifungal Therapies
Table 1. Select Fungi That Can Cause Serious Systemic Fungal Infections
Table 2. Select Antifungal Drugs for the Treatment of Systemic Fungal Infections
Table 3. Select Companies with Antifungals in Clinical Development
Table 4. Select Companies with Antifungals in Preclinical Development
Table 5. Estimated Worldwide Sales of Antifungal Products, 2003 and 2008 (millions of U.S. dollars)

Companies Mentioned

- Ace BioSciences and Genmab - Biodelivery Sciences International - Diversa - Ecopia BioSciences - Elitra Pharmaceuticals - Entomed - Enzonb/Zeneus Pharma - Fujisawaa - Genelabs Technologies - Helix BioMedix - Immtech International - Inhibitex - InterMune Pharmaceuticals - Janssen Pharmaceutica - Janssen Pharmaceutica - Merck & Co. - MycoLogics - Paratek Pharmaceuticals - Pfizer - Pfizer - Schering-Plough - Valeant Pharmaceuticals - Vicuron Pharmaceuticals

Ordering:

Order Online - visit http://www.researchandmarkets.com/reports/314589

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Page 1 of 2
Printed 12/02/2012 23:56:42

Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to
646-607-1907 (from USA) or +353 1 6849977 (from Rest of World). If you have any questions please email help@researchandmarkets.net

Order information
Please verify that the product information is correct and select the format you require.


Product Name:
Advances in the Treatment of Serious Systemic Fungal Infections--An Update
Web Address:
http://www.researchandmarkets.com/reports/314589
Office Code:
OC8IHINLSNNSS

Report formats
Please enter the quantity of the report format you require.

	Format	Quantity	Price
	Electronic (PDF) - Single User		€774.00

Contact information
Please enter all the information below in BLOCK CAPITALS.


	First Name:	Last Name:
	Email Address:
	Job Title:
	Organisation:
	Address:
	City:
	Postal/Zip Code:
	Country:
	Phone Number:
	Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Page 2 of 2
Printed 12/02/2012 23:56:42

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

	American Express
	Diners Club
	Master Card
	Visa


Cardholder's Name:

Cardholder's Signature:

Expiry Date:	/

Card Number:

CVV Security Code:

Issue Date:	/ (Diners Club only)

Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Pay by Wire Transfer:

Please transfer funds to:


Account number:	83313083
Sort code:	98-53-30
Swift code:	ULSBIE2D
IBAN number:	IE78ULSB98533083313083
Bank Address:	Ulster Bank, 27-35 Main St, Blackrock, Co. Dublin, Ireland.

If you have a Marketing Code please enter it below:
	Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)